The impact of COVID-19 on tuberculosis: challenges and opportunities

被引:17
作者
Kant, Surya [1 ]
Tyagi, Richa [1 ]
机构
[1] King Georges Med Univ, Dept Resp Med, Lucknow 226003, UP, India
关键词
tuberculosis control; COVID-19; SARS-CoV-2; impact; chronic respiratory diseases; PHAGOSOME MATURATION;
D O I
10.1177/20499361211016973
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a seafood market in Wuhan, China, has ushered in a new era. It transformed into a pandemic, seized global attention, and was the biggest highlight of the year 2020. The SARS-CoV-2 outbreak has jeopardized health systems and greatly affected socioeconomic parameters. With global focus on fighting this unpredictable fight with this new virus, the biggest chronic infectious killer, mycobacterium tuberculosis (M. tb), was hugely affected from this shift in attention. Due to certain similarities in the behavior of the two infectious agents, there have been inevitable consequences. On one hand, administrative measures to contain SARS-CoV-2 have simultaneously led to a breaking in the chain of tuberculosis (TB) management. Consequently, a regression occurred in the milestones achieved in the battle against TB. On the other hand, the same measures and heightened hygiene awareness has helped to decrease the spread of the TB bacilli. With an improved understanding of the interrelations and the outcomes noticed in 2020, we can better gear ourselves to develop a more sophisticated and robust strategy to tilt the balance against TB. Keeping this in mind, in this review we aim to discuss in detail the implications of SARS-CoV-2 on an already unwavering health hazard: TB.
引用
收藏
页数:7
相关论文
共 55 条
[1]  
[Anonymous], 2020, National Tuberculosis Elimination Program
[2]  
[Anonymous], 2020, WHO directorgeneral's opening remarks at the media briefing on COVID-19 - 11 March 2020
[3]  
Barberis I, 2017, J Prev Med Hyg, V58, pE9
[4]  
CAVE A. J. E., 1939, BRIT JOUR TUBERC, V33, P142, DOI 10.1016/S0366-0850(39)80016-3
[5]   Clinical and immunological features of severe and moderate coronavirus disease 2019 [J].
Chen, Guang ;
Wu, Di ;
Guo, Wei ;
Cao, Yong ;
Huang, Da ;
Wang, Hongwu ;
Wang, Tao ;
Zhang, Xiaoyun ;
Chen, Huilong ;
Yu, Haijing ;
Zhang, Xiaoping ;
Zhang, Minxia ;
Wu, Shiji ;
Song, Jianxin ;
Chen, Tao ;
Han, Meifang ;
Li, Shusheng ;
Luo, Xiaoping ;
Zhao, Jianping ;
Ning, Qin .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05) :2620-2629
[6]   Old Testament biblical references to tuberculosis [J].
Daniel, VS ;
Daniel, TM .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) :1557-1558
[7]  
Directorate of Health Services Ministry of Health Family Welfare and Government of India CTD, NATL STRAT PLAN TUB
[8]  
Flick L F., 1925, Development of our knowledge of tuberculosis
[9]  
Frith J, 2014, J MIL VET HLTH, P22
[10]   The epidemiology and clinical information about COVID-19 [J].
Ge, Huipeng ;
Wang, Xiufen ;
Yuan, Xiangning ;
Xiao, Gong ;
Wang, Chengzhi ;
Deng, Tianci ;
Yuan, Qiongjing ;
Xiao, Xiangcheng .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020, 39 (06) :1011-1019